Our Mission
Rebuild Cells Rescue Lives
Our Vision
Create Miracles with Technology
Our Values
Focus，Innovation，Inclusiveness，Sharing
About Us
Founded in 2019, Juncell Therapeutics has been hailed as a "unicorn company" for developing innovative TIL therapies in the field of solid tumor treatment. As a national high-tech enterprise and one of "Shanghai Specialized and Innovative Enterprises", we are currently at the stage of clinical research. In addition, we won the highest award "Excellence Award" in the "National Disruptive Technology Innovation Competition" organized by the Ministry of Science and Technology of China, and was selected as a candidate for disruptive technology in MOST's database.
Juncell Therapeutics has established a facility platform covering 3,000m2 including 2,000m2 GMP production workshops and quality control laboratories, with a supporting quality management system. And over 16,000㎡ commercial production is under construction in stages. By virtue of the innovative DeepTIL® cell expansion platform and the NovaGMP® gene modification platform, our company has developed a series of natural TIL and non-viral vector-based genetically modified TIL therapies, among which, 2 piplines are in clinical trials.
Core Technology
-
DeepTIL®cell expansion platform
☛ Highly efficient TIL enrichment for all tumor types
Clinical-grade TILs can be obtained with a high successful rate ＞90%.
☛ Simplified process without feeder cells
The expansion of TILs becomes easier and cheaper with no healthy human PBMCs.
☛ No lymphodepletion pre-treatment or IL-2 injections
Patients can receive treatment just in general wards.
-
NovaGMP®gene modification platform
☛ Safer
No risk of wild-type virus mutaions.
☛ Cheaper
The non-viral vector-based gene modification costs less than 1/10 of the viral vectors system.
☛ More efficient
TILs have stronger anti-tumor activity and in vivo adaptation capability with transfection efficiency ＞45% .
-
Sufficient cellsThe same process；High successful cultivation rate＞90%
-
Competent cellsBillion level cells；Highly specific T cells
-
AffordableFeeder cells-free；Non-viral vector at a low cost
-
Clinically applicableLess intensive pretreatment；IL-2 injection-free
Clinical Trials
-
A Phase I clinical trial of the autologous natural TIL (GC101) for the treatment of advanced malignant solid tumorsChinese PLA General Hospital -
A Phase I clinical trial of the autologous natural TIL (GC101) for the treatment of advanced malignant solid tumorsFudan University Shanghai Cancer Center -
A Phase I clinical trial of the autologous natural TIL (GC101) for the treatment of advanced malignant solid tumorsTenth People's Hospital of Tongji University -
A clinical study of TILs expressing membrane-bound cytokines for the treatment of advanced gynecologic tumorsTenth People's Hospital of Tongji University
News
Partners
